SCHEDULE 13D: Activist Investor ADAR1 Capital Management Urges Keros Therapeutics to Pursue Strategic Alternatives, Citing Undervaluation and Drug Viability Concerns

ADAR1 Capital Management, holding a 13.29% stake in Keros Therapeutics, has filed a Schedule 13D, expressing concerns over the viability of KER-012 and KER-065 and urging the company to explore strategic options including share buybacks, significant workforce reductions, potential sale, or liquidation to maximize shareholder value.

Summary

• ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger (collectively, 'Reporting Persons') have disclosed a combined beneficial ownership of 5,390,964 shares of Keros Therapeutics, Inc. common stock, representing 13.29% of the outstanding shares.
• The Reporting Persons acquired their stake for investment purposes, believing Keros Therapeutics' common stock is undervalued.
• They have communicated concerns to the Issuer regarding the limited viability of KER-012 and KER-065, based on recent safety and efficacy data.
• The Reporting Persons estimate the company's Net Asset Value (NAV) per share to range from $24 to $35, factoring in a $300 million to $750 million valuation for the Takeda partnership and net cash in a liquidation scenario.
• They have strongly urged Keros Therapeutics' management and board to consider operational and strategic opportunities, including an accelerated share buyback or tender offer, a 70% reduction in force to minimize cash burn, strategic alternatives (company sale, outlicensing/divesting KER-012/KER-065, monetization of Takeda royalties/milestones), or, if alternatives don't materialize quickly, initiation of liquidation proceedings and reduction of annual cash burn to less than $3 million.
• The Reporting Persons believe that systematic accretive buybacks, tender offers, and dividends could ultimately deliver between $40 and $50 per share for shareholders who remain invested through the potential approval and launch of Elritercept.
• Keros Therapeutics adopted a rights plan on April 9, 2025, publicly announced on April 10, 2025, after which the Reporting Persons have not acquired additional shares under the plan.
• The Reporting Persons intend to continue dialogue with the Issuer's management and Board, as well as other stakeholders, and may adjust their investment based on various factors.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the filing highlights significant concerns about current drug viability and undervaluation, the Reporting Persons' actions and proposals are driven by a strong belief in the company's underlying potential and a clear path to unlock substantial shareholder value (e.g., $40-$50 per share with Elritercept), indicating an optimistic outlook if their strategic recommendations are adopted.

Positives

• Reporting Persons believe Keros Therapeutics' common stock is undervalued, trading at a substantial discount to their estimated NAV per share of $24 to $35.
• The Takeda partnership is valued by the Reporting Persons at $300 million to $750 million, indicating a significant asset.
• Proposed strategic actions, such as systematic accretive buybacks, tender offers, and dividends, are believed to potentially deliver $40 to $50 per share for long-term shareholders, suggesting significant upside potential.
• The Reporting Persons are actively engaging with management and the Board to unlock shareholder value.

Negatives

• Reporting Persons have concerns regarding the limited viability of KER-012 and KER-065 based on recent safety and efficacy data.
• The market is perceived to be agreeing with the assessment of limited viability, leading to the shares trading at a substantial discount to NAV.
• The company's current cash burn is a concern, prompting a recommendation for a 70% reduction in force and a target annual cash burn of less than $3 million.

Risks

• Limited viability of KER-012 and KER-065 due to safety and efficacy data, potentially impacting future revenue streams and pipeline value.
• Continued high cash burn if operational efficiencies and strategic alternatives are not implemented, potentially eroding shareholder value.
• Failure to successfully execute proposed strategic alternatives (e.g., company sale, outlicensing, monetization of royalties) could lead to further value destruction.
• The Issuer's adoption of a rights plan could complicate or deter further activist actions or hostile takeovers.

Future Outlook

The Reporting Persons intend to review their investment in Keros Therapeutics on an ongoing basis and may acquire or dispose of additional securities, enter into financial instruments, or change their intentions based on discussions with the Issuer, the company's financial performance, strategic direction, market conditions, and other investment opportunities. They believe that through systematic accretive buybacks, tender offers, and dividends, the company could deliver $40 to $50 per share to shareholders who remain invested through the potential approval and launch of Elritercept.

Management Comments

• The Reporting Persons have communicated to the Issuer concerns with recent safety and efficacy data which the Reporting Persons believe indicate limited viability of KER-012 and KER-065.
• In the opinion of the Reporting Persons, the market is agreeing with this assessment as the shares were trading at a substantial discount to NAV per share.
• As a result of those concerns, the Reporting Persons have strongly urged the Issuer and its management and board of directors to consider operational and strategic opportunities to maximize shareholder value.

Industry Context

This Schedule 13D filing represents an activist investor taking a significant stake in a biotechnology company, Keros Therapeutics, and publicly challenging its current strategy and pipeline assets. Such filings are common in the biotech sector where companies with promising but unproven assets, or those perceived as undervalued, become targets for investors seeking to unlock value through strategic shifts, cost reductions, or asset monetization. The focus on specific drug candidates (KER-012, KER-065, Elritercept) and a major partnership (Takeda) highlights the asset-centric nature of biotech investing and the potential for activist pressure to drive changes in R&D focus or corporate structure.

Comparison to Industry Standards

• The proposed 70% reduction in force and target annual cash burn of less than $3 million are aggressive cost-cutting measures, often seen in biotech companies facing pipeline setbacks or seeking to extend their cash runway significantly, potentially to a level more typical of a pre-clinical or early-stage company rather than one with multiple clinical assets.
• The call for an accelerated share buyback or tender offer is a common activist tactic for companies with substantial cash reserves and a perceived undervalued stock, aiming to return capital to shareholders and boost per-share metrics, similar to actions seen in mature industries or larger biotech firms with excess capital.
• The suggestion of strategic alternatives, including a company sale, outlicensing, or divestiture of specific assets (KER-012, KER-065), aligns with standard practices in the biotech industry for maximizing value from pipeline assets, especially when internal development is deemed inefficient or less promising.
• The ultimate proposal of liquidation, if attractive strategic alternatives do not materialize, is a more extreme but not unprecedented activist demand, typically reserved for companies where the sum of parts is believed to be greater than the market capitalization, or where continued operations are seen as value-destructive.

Corporate Governance

Related Party Transactions

• The Reporting Persons (ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger) entered into a Joint Filing Agreement to jointly file this Schedule 13D and any amendments.

Stakeholder Impact

• Shareholders: Potential for significant value creation if the Reporting Persons' proposed strategies (e.g., buybacks, strategic sale, Elritercept approval) are successfully implemented, potentially leading to $40-$50 per share. Conversely, current undervaluation and concerns about pipeline assets could lead to continued share price pressure if no changes occur.
• Employees: A proposed 70% reduction in force would have a severe negative impact on a significant portion of the workforce.
• Customers/Patients: Potential impact on the development and availability of KER-012 and KER-065 if these programs are divested, outlicensed, or discontinued.
• Suppliers/Creditors: Potential impact on business relationships and financial obligations depending on the strategic direction taken (e.g., liquidation, significant operational changes).
• Takeda (Partner): Potential for changes in the Takeda partnership, including monetization of royalties and milestones, which could alter the terms or nature of their collaboration.

Next Steps

• Reporting Persons intend to have a dialog with Keros Therapeutics' management regarding their proposed strategic and operational changes.
• Reporting Persons may also speak with members of the Board, other current or prospective shareholders, industry analysts, existing or potential strategic partners or competitors, investment and financing professionals, sources of credit, and other third parties.
• Reporting Persons may acquire additional shares or other securities of the Issuer, or dispose of some or all of their beneficially owned securities.
• Reporting Persons may enter into financial instruments or other agreements that increase or decrease their economic exposure to the Issuer.
• Keros Therapeutics' management and Board are urged to consider instituting an accelerated share buyback or tender offer.
• Keros Therapeutics' management and Board are urged to consider implementing a significant reduction in force of seventy percent.
• Keros Therapeutics' management and Board are urged to pursue strategic alternatives, including the potential sale of the Company, outlicensing or divesting KER-012, KER-065, or monetization of Takeda royalties and milestones.
• If attractive strategic alternatives do not materialize quickly, Keros Therapeutics' management and Board are urged to initiate liquidation proceedings and reduce annual cash burn to less than $3 million.

Key Dates

Recommendation

Keywords

Keros Therapeutics, ADAR1 Capital Management, Activist Investor, Schedule 13D, Shareholder Value, Undervaluation, Strategic Alternatives, Share Buyback, Tender Offer, Cash Burn Reduction, Liquidation, KER-012, KER-065, Elritercept, Takeda Partnership, Biotechnology, Pharmaceuticals